Jupiter Topco LLC Makes New $866,000 Investment in Relay Therapeutics, Inc. $RLAY

Jupiter Topco LLC acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 46,273 shares of the company’s stock, valued at approximately $866,000.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Relay Therapeutics in the second quarter worth approximately $286,042,000. Commodore Capital LP purchased a new position in shares of Relay Therapeutics during the second quarter worth approximately $46,191,000. Perceptive Advisors LLC lifted its holdings in shares of Relay Therapeutics by 412.3% in the 1st quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after acquiring an additional 7,847,896 shares during the last quarter. Spruce Street Capital LP bought a new stake in shares of Relay Therapeutics in the 4th quarter worth approximately $25,246,000. Finally, EcoR1 Capital LLC purchased a new stake in shares of Relay Therapeutics in the 1st quarter valued at $18,952,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Price Performance

RLAY stock opened at $19.04 on Friday. The business has a fifty day moving average price of $19.36 and a 200-day moving average price of $15.08. Relay Therapeutics, Inc. has a 1-year low of $3.86 and a 1-year high of $21.27. The stock has a market capitalization of $4.17 billion, a P/E ratio of -12.13 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.96 million. As a group, analysts anticipate that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the completion of the sale, the chief financial officer directly owned 177,461 shares in the company, valued at approximately $3,011,513.17. The trade was a 51.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Donald Bergstrom sold 93,456 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.94, for a total transaction of $1,583,144.64. Following the sale, the insider directly owned 418,557 shares of the company’s stock, valued at approximately $7,090,355.58. This represents a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,414,147 shares of company stock valued at $123,723,695 in the last 90 days. 5.04% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

RLAY has been the topic of several analyst reports. JonesTrading upgraded Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. HC Wainwright increased their price target on shares of Relay Therapeutics from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Guggenheim restated a “buy” rating on shares of Relay Therapeutics in a research report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Relay Therapeutics in a report on Monday, August 10th. Finally, The Goldman Sachs Group raised their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.92.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.